Drug class profile · refreshed daily from federal data

Insulin Analog

16 molecules in this class, $5.21B combined CY2024 Part D spend across 14.1M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Insulin Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 16tracked in Part D
CY24 Part D spend: $5.21Bcombined across class
Total Rx claims: 14.1M5.3M unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Insulin Degludec

Brand: TRESIBA · 3.5M Part D claims (CY24) · 1.2M beneficiaries · First FDA approval: 2015-09-25

Brand-only (no generics) 3 plans require PA Discontinued

Low NADAC$9.02

→

Avg plan cost$13.60

Part D spend $2.69B 2× spread, current vs floor

Class share

52%

of class CY24 spend

View profile →

02

Insulin Lispro

Brand: ADMELOG · 5.2M Part D claims (CY24) · 2.0M beneficiaries · First FDA approval: 1996-06-14

Brand-only (no generics) 100 plans require PA Discontinued

Low NADAC$2.40

→

Avg plan cost$10.15

Part D spend $1.35B 4× spread, current vs floor

Class share

26%

of class CY24 spend

View profile →

03

Insulin Aspart

Brand: .Insulin Aspart Protamine and Insulin Aspart · 3.4M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2001-08-27

Brand-only (no generics) 92 plans require PA Discontinued

Low NADAC$6.93

→

Avg plan cost$8.11

Part D spend $704.9M 1× spread, current vs floor

Class share

14%

of class CY24 spend

View profile →

04

Insulin Glargine-Yfgn

Brand: INSULIN GLARGINE · 1.1M Part D claims (CY24) · 515K beneficiaries · First FDA approval: 2023-07-28

Brand-only (no generics) 0 plans require PA

Low NADAC$2.90

→

Avg plan cost$11.60

Part D spend $168.2M 4× spread, current vs floor

Class share

3%

of class CY24 spend

View profile →

05

Insulin Detemir

Brand: LEVEMIR · 725K Part D claims (CY24) · 275K beneficiaries · First FDA approval: 2006-03-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $155.5M

Class share

3%

of class CY24 spend

View profile →

06

Insulin Lispro-Aabc

Brand: LYUMJEV · 154K Part D claims (CY24) · 56K beneficiaries · First FDA approval: 2020-06-15

Brand-only (no generics) 33 plans require PA Discontinued

Low NADAC$7.87

→

Avg plan cost$12.11

Part D spend $139.8M 2× spread, current vs floor

Class share

3%

of class CY24 spend

View profile →

07

Insulin Glulisine

Brand: Apidra · 15K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2009-02-24

Brand-only (no generics) 3 plans require PA

Low NADAC$8.16

→

Avg plan cost$9.33

Part D spend $4.4M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

08

Insulin Glargine-Aglr

Brand: REZVOGLAR KWIKPEN · 13K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2021-12-17

Brand-only (no generics) 1 plans require PA

Low NADAC$5.92

→

Avg plan cost$5.92

Part D spend $1.1M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

09

Diluent

Brand: Sterile Diluent · — Part D claims (CY24) · First FDA approval: 1987-07-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

10

Insulin Aspart Injection

Brand: Fiasp · — Part D claims (CY24) · First FDA approval: 2017-10-20

Brand-only (no generics) 91 plans require PA

Low NADAC$6.92

→

Avg plan cost$8.13

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

11

Insulin Aspart-Szjj

Brand: MERILOG · — Part D claims (CY24) · First FDA approval: 2025-02-14

Brand-only (no generics) 1 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

12

Insulin Aspart-Xjhz

Brand: KIRSTY · — Part D claims (CY24) · First FDA approval: 2025-09-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

13

Insulin Degludec and Liraglutide

Brand: Xultophy 100/3.6 · — Part D claims (CY24) · First FDA approval: 2016-11-21

Brand-only (no generics) 0 plans require PA

Low NADAC$85.89

→

Avg plan cost$85.89

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

14

Insulin Glargine

Brand: BASAGLAR · — Part D claims (CY24) · First FDA approval: 2009-09-23

Brand-only (no generics) 3 plans require PA Discontinued

Low NADAC$6.15

→

Avg plan cost$39.47

Part D spend — 6× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

15

Insulin Glargine and Lixisenatide

Brand: Soliqua 100/33 · — Part D claims (CY24) · First FDA approval: 2016-11-21

Brand-only (no generics) 0 plans require PA

Low NADAC$57.06

→

Avg plan cost$57.06

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

16

Water Injection

Brand: Insulin Diluting Medium for NovoLog · — Part D claims (CY24) · First FDA approval: 2001-08-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →